Veterinary

Covetrus Completes Sale of scil animal care to Heska

Wednesday, April 1, 2020 - 2:00pm

Covetrus (NASDAQ: CVET), a global leader in animal-health technology and services, today announced that it has completed the sale of its scil animal care business (scil) to Heska Corporation (Heska) (NASDAQ: HSKA).

Key Points: 
  • Covetrus (NASDAQ: CVET), a global leader in animal-health technology and services, today announced that it has completed the sale of its scil animal care business (scil) to Heska Corporation (Heska) (NASDAQ: HSKA).
  • The transaction closed under an amended purchase agreement which reduced the total consideration paid to Covetrus from $125 million to $110 million.
  • The scil business is in great hands with a high-quality partner in Heska and we are appreciative of their commitment to the business and the scil team during these unprecedented times, said Ben Wolin, Covetrus president and chief executive officer.
  • Covetrus is a global animal-health technology and services company dedicated to empowering veterinary practice partners to drive improved health and financial outcomes.

Zoetis to Host Webcast and Conference Call on First Quarter 2020 Financial Results

Wednesday, April 1, 2020 - 1:30pm

(NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Wednesday, May 6, 2020.

Key Points: 
  • (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Wednesday, May 6, 2020.
  • Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Glenn David will review first quarter 2020 financial results and respond to questions from financial analysts during the call.
  • Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations .
  • A replay of the webcast will be made available on May 6, 2020.

Global Animal Parasiticides Market Analysis, Trends, and Forecasts 2019-2025 - ResearchAndMarkets.com

Wednesday, April 1, 2020 - 10:40am

Animal Healthcare Market Worldwide: Revenues in US$ Billion for the Years 2018, 2020, 2022 and 2024

Key Points: 
  • Animal Healthcare Market Worldwide: Revenues in US$ Billion for the Years 2018, 2020, 2022 and 2024
    With Demand for Protein Rich, Animal-Derived Foods Continuing to Grow, Parasiticides Market is Poised for Growth
    World Population (in Thousands) by Geographic Region for the Years 2018, 2025, 2040, 2050
    Number of Veterinarians in the US by Gender for the Years 2016, 2017 and 2018
    Countries with Highest Proportion of Vegetarian Diet: Vegetarianism as % of Total Population for the Year 2018
    Developing Oral Forms of Ectoparasiticides: An Area of Focus for Market Players
    Resistance to Antiparasitics in Animals: A Major Concern

ELITechGroup’s Staining Technology Expands with Aerospray® Cytology Slide Stainer/Cytocentrifuge

Tuesday, March 31, 2020 - 5:20pm

ELITechGroup Inc., recognized worldwide as slide staining and cytocentrifuge technologic pioneers and innovators, with nearly 30 patents, over the 35-year lifespan of Aerospray staining technology, announces the launch of the Aerospray Cytology Slide Stainer Cytocentrifuge.

Key Points: 
  • ELITechGroup Inc., recognized worldwide as slide staining and cytocentrifuge technologic pioneers and innovators, with nearly 30 patents, over the 35-year lifespan of Aerospray staining technology, announces the launch of the Aerospray Cytology Slide Stainer Cytocentrifuge.
  • The ELITechGroups Aerospray Cytology Slide Stainer/Cytocentrifuge automates the preparation and staining of liquid based cytology specimens to facilitate the examination of an array of cell differentiations utilizing Papanicolaou staining techniques.
  • The advantages of the Aerospray Cytology Slide Stainer/Cytocentrifuge is that the device performs two functions of sample preparation through cytocentrifugation and sample staining.
  • ELITechGroups portfolio of Aerospray slide stainers and cytocentrifuges has enabled the company to develop a worldwide reputation for performance and reliability.

Global Animal Genetics Market Analysis and Forecast, 2019-2024 - ResearchAndMarkets.com

Tuesday, March 31, 2020 - 12:32pm

The "Global Animal Genetics Market: Focus on Solutions, Product Type, Industry Analysis and Forecast, 2019-2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Animal Genetics Market: Focus on Solutions, Product Type, Industry Analysis and Forecast, 2019-2024" report has been added to ResearchAndMarkets.com's offering.
  • Key Questions Answered in this Report:
    What is the global animal genetics market size in terms of revenue, and what is the expected growth rate during the forecast period 2019-2024?
  • What are the major forces that are expected to increase the demand for the global animal genetics market during the forecast period?
  • What are the major challenges inhibiting the growth of the global animal genetics market?

Cubic Partners with University of Alabama in Huntsville for a Prototype Ventilator in Support of COVID-19 Efforts

Tuesday, March 31, 2020 - 12:02pm

Cubics Huntsville operations is the main development and manufacturing facility for its Cubic Mission Solutions business divisions GATR satellite communication and networking systems.

Key Points: 
  • Cubics Huntsville operations is the main development and manufacturing facility for its Cubic Mission Solutions business divisions GATR satellite communication and networking systems.
  • The GATR team has repurposed off-the-shelf inflation components of the ISA to develop the compact VentiGATR prototype that is being used for testing.
  • As a technology-driven, market-leading global provider of innovative solutions, we hope to support in any way we can during this COVID-19 pandemic.
  • Cubic would like to thank the local Huntsville community for its support as the company works to provide emergency capability during this pandemic crisis.

FDA Approves Next-Generation ZOLL® TherOx System for Widowmaker Heart Attack Patients

Monday, March 30, 2020 - 2:23pm

We are pleased to provide the interventional cardiologist with a new treatment that augments the standard of care for patients.

Key Points: 
  • We are pleased to provide the interventional cardiologist with a new treatment that augments the standard of care for patients.
  • More than 30% of severe heart attack patients develop heart failure,3 and of those, 50% will die within five years.3 SSO2 Therapy has been shown in prospective clinical trials to safely reduce infarct size in widowmaker heart attack patients5.
  • Decades of research on heart attack patients has demonstrated that infarct size reduction is correlated with reduced mortality and heart failure, and better left ventricular function.4
    SSO2 Therapy was developed by Irvine, California-based TherOx, Inc., now part of ZOLL Medical Corporation.
  • TherOx and ZOLL are trademarks and/or registered trademarks of ZOLL Medical Corporation in the United States and/or other countries.

Intensity Therapeutics Reports Safety Results from First Cohort of the KEYNOTE A10 Combination Clinical Trial of INT230-6 and Keytruda®

Monday, March 30, 2020 - 12:35pm

Patientss tumors were treated every two weeks for 5 doses with INT230-6 in combination with 200 mg of Keytruda every three weeks.

Key Points: 
  • Patientss tumors were treated every two weeks for 5 doses with INT230-6 in combination with 200 mg of Keytruda every three weeks.
  • Following completion of the dosing of INT230-6, patients continue on Keytruda monotherapy for up to 2 years.
  • Intensity also plans a fourth phase 2 cohort to test the combination in squamous cell carcinoma patients who have already failed a PD1/PDL1 agent.
  • The confirmation of safety in our first combination cohort marks an important milestone in our evaluation of INT230-6 dosed with Keytruda, commented Lewis H. Bender , President and Chief Executive Officer of Intensity Therapeutics.

The Elanco Foundation Announces Efforts to Support Food Security Amidst COVID-19 Crisis

Friday, March 27, 2020 - 12:30pm

The funds will support organizations and food banks in communities across Elanco Animal Healths (NYSE: ELAN) footprint, including Gleaners Food Bank of Indiana , the European Food Banks Federation and food banks in Winslow, Maine, Ft.

Key Points: 
  • The funds will support organizations and food banks in communities across Elanco Animal Healths (NYSE: ELAN) footprint, including Gleaners Food Bank of Indiana , the European Food Banks Federation and food banks in Winslow, Maine, Ft.
  • The Elanco Foundation will continue to monitor the emerging food security issues arising from the COVID-19 crisis in other regions of the globe.
  • These efforts align with the focus of the new Elanco Foundation, which is committed to philanthropic investments, strategic partnerships and volunteer engagements connected to food security and the human-animal bond.
  • Food security efforts will strive to improve health of people through increased access to animal protein from food systems, sustainable farming, and protein education.

IGC Receives New Patent from U.S. Patent Office to Treat Cachexia and Eating Disorders in Humans and Veterinary Animals

Friday, March 27, 2020 - 12:30am

IGC filed this application for its IGC-504 formulation (#15/751,901) on August 11, 2016.

Key Points: 
  • IGC filed this application for its IGC-504 formulation (#15/751,901) on August 11, 2016.
  • A public copy of the patent is available on the USPTO website.
  • A patent for an invention is the grant of a property right to the inventor, issued by the USPTO.
  • The company is based in Maryland, U.S.A. Our website: www.igcinc.us .Twitter @IGCIR
    View source version on businesswire.com: https://www.businesswire.com/news/home/20200326005803/en/